David Bouchey
Stock Analyst at Aegis Capital
(n/a)
# 4,373
Out of 4,734 analysts
7
Total ratings
n/a
Success rate
-54.52%
Average return
Main Sectors:
Stocks Rated by David Bouchey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SBFM Sunshine Biopharma | Reiterates: Buy | $15 | $2.91 | +415.46% | 2 | Dec 5, 2024 | |
| STSS Sharps Technology | Initiates: Buy | $352 | $1.88 | +18,623.40% | 1 | May 9, 2023 | |
| ATXI Avenue Therapeutics | Initiates: Buy | $2,400 | $1.85 | +129,629.73% | 1 | Apr 3, 2023 | |
| IINN Inspira Technologies Oxy B.H.N. | Maintains: Buy | $10 → $13 | $1.10 | +1,081.82% | 1 | Jan 25, 2023 | |
| RMTI Rockwell Medical | Downgrades: Outperform | $121 | $2.19 | +5,425.11% | 2 | Oct 19, 2018 |
Sunshine Biopharma
Dec 5, 2024
Reiterates: Buy
Price Target: $15
Current: $2.91
Upside: +415.46%
Sharps Technology
May 9, 2023
Initiates: Buy
Price Target: $352
Current: $1.88
Upside: +18,623.40%
Avenue Therapeutics
Apr 3, 2023
Initiates: Buy
Price Target: $2,400
Current: $1.85
Upside: +129,629.73%
Inspira Technologies Oxy B.H.N.
Jan 25, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $1.10
Upside: +1,081.82%
Rockwell Medical
Oct 19, 2018
Downgrades: Outperform
Price Target: $121
Current: $2.19
Upside: +5,425.11%